Polyethylene glycol-conjugated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) primary prophylaxis significantly reduces the duration of neutropenia in non-Hodgkin's lymphoma patients treated with chemotherapy: a randomised trial (NCT05834751).

ABSTRACT:

Background

Neutropenia is one of the most common complications of chemotherapy in lymphoma patients. To treat and prevent this condition, polyethylene glycol-conjugated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF; mecapegfilgrastim) has been developed. This study compared the efficacy of PEG-rhG-CSF with that of recombinant human granulocyte colony-stimulating factor (G-CSF) in preventing neutropenia after chemotherapy for lymphoma.

Methods

A prospective randomized study of 154 patients with lymphoma admitted to The First Hospital of Jilin University from September 2020 to September 2022 was conducted. The predetermined sample size is established with a power analysis-driven approach, followed by rigorous non-inferiority testing to evaluate therapeut

SUBMITTER: Wang B 

PROVIDER: S-EPMC12776184 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature